Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study tested a folate-conjugate drug delivery system and found its cytotoxicity depends on whether the treated cells overexpress folate receptors, suggesting potential for targeted chemotherapy.

This article reviews triamcinolone acetonide as an intramuscular long-acting steroid therapy for dermatologic disorders but reports no new clinical results.

Tofacitinib may effectively treat folliculitis decalvans.

This study found that glibenclamide exhibited a cytostatic effect on MDA-MB-231 breast cancer cells, potentially mediated through K ATP channels, and enhanced the antiproliferative impact of doxorubicin.

This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.

In this case report, a 24-year-old woman with Down syndrome effectively managed coexisting alopecia areata and hidradenitis suppurativa using upadacitinib, following partial success with previous treatments.

This literature review found that Janus kinase inhibitors may help achieve remission in patients with refractory primary neutrophilic cicatricial alopecias, though data is limited to small case series and reports.

This article suggests that a topical sulfonylurea drug may inhibit excessive hair growth caused by diazoxide without affecting its beneficial effects on beta cells, potentially offering a treatment for various forms of hypertrichosis and hirsutism.

This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.

This review discusses the diverse pharmacological activities of T. procumbens, such as hypotensive and hair growth-promoting effects, but reports no new clinical findings.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

This study found that the CXXC5 protein is overexpressed in diabetic foot ulcer tissues, suppressing wound healing, and that the small molecule KY19334 accelerated healing in diabetic mice by activating the Wnt/β-catenin pathway.

This report suggests that tofacitinib may be beneficial for patients with nail disease unresponsive to other treatments.

In two phase 3 clinical trials, this study found that adults with severe alopecia areata receiving baricitinib experienced significant hair regrowth on the scalp, eyebrows, and eyelashes over 36 weeks compared to placebo, although longer-term data are needed to fully assess benefits and risks.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

This study documented a case where the medication baricitinib effectively promoted hair regrowth in a woman with alopecia areata but also led to an unexpected side effect of hypertrichosis, suggesting a need to further explore the JAK/STAT pathway's role in hair growth dynamics.

In a guinea pig model of dermatophytosis, this study found that subcutaneous CD101, dosed once weekly, demonstrated significant clinical and mycological efficacy compared to the vehicle control and the oral antifungal terbinafine, suggesting potential for CD101 in treating fungal skin infections.

This abstract details known indications, categories, and potential reactions for various drugs, including anorexiants, estrogens, NSAID analgesics, cardiac glycosides, and migraine preventives, without reporting new clinical results.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study reports that the β-catenin inhibitor tegatrabetan reduced hair growth and hair follicle numbers in mice, suggesting its potential as a model for developing new hair growth materials.

In this study, the methanolic extract of Tridax procumbens Linn demonstrated significant antiulcer activity in a mice model of acetic acid-induced ulcerative colitis, offering 57.12% ulcer protection compared to 50.60% by the standard drug prednisolone.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.